{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:31:38Z","timestamp":1784597498481,"version":"3.55.0"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>To investigate pneumothorax patterns in pazopanib treatment by focusing on the positional relationship between the visceral pleura and metastatic lung tumor, we examined 20 patients with advanced soft tissue tumors who developed lung metastases and underwent pazopanib treatment between 2012 and 2019. Pneumothorax was classified into two types based on the location of the metastatic lesion around the visceral pleural area before pazopanib treatment: subpleural type, within 5 mm from the pleura; and central type, &gt;5 mm from the pleura. We investigated the rates of pneumothorax and the associated risk factors. Five patients experienced pneumothorax (three subpleural and two central types). Cavitation preceded pneumothorax in 83% of patients and led to connection of the cavitated cyst of the metastatic lesion to the chest cavity in the shorter term in patients with the subpleural type. Conversely, a more gradual increase in the cavity size and sudden cyst rupture were observed in the central type. The risk factors for pneumothorax were cavitation after initiating pazopanib and intervention before pazopanib, either ablation or surgery. The location of the metastatic lesions was not a risk factor for the occurrence of pneumothorax. In conclusion, pneumothorax is an adverse event associated with pazopanib treatment. Therefore, attention must be paid to predisposing factors such as the formation of cavitation after pazopanib initiation and previous interventions to the lungs. Moreover, because subpleural pneumothorax tends to occur earlier than the central type, a different time course can be anticipated based on the positional relationships of the metastatic lesions to the visceral pleura.<\/jats:p>","DOI":"10.1371\/journal.pone.0254866","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T17:40:00Z","timestamp":1626457200000},"page":"e0254866","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-9814","authenticated-orcid":true,"given":"Hisaki","family":"Aiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Tatematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"pone.0254866.ref001","first-page":"1879","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"pone.0254866.ref002","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.clon.2014.02.010","article-title":"Incidence of pneumothorax in advanced and\/or metastatic soft tissue sarcoma patients during pazopanib treatment","volume":"26","author":"K Nakano","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"9","key":"pone.0254866.ref003","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.29961","article-title":"The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study","volume":"122","author":"T Nakamura","year":"2016","journal-title":"Cancer"},{"key":"pone.0254866.ref004","unstructured":"Evaluation and Licensing Division [Internet]. Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare Report on the Deliberation Results [Cited 29 June 2019]. Available from: https:\/\/www.pmda.go.jp\/files\/000153553.pdf."},{"issue":"Suppl 2","key":"pone.0254866.ref005","first-page":"ii18","article-title":"Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010","volume":"65","author":"BTS Pleural Disease Guideline Group","year":"2010","journal-title":"Thorax"},{"issue":"5","key":"pone.0254866.ref006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/emj.15.5.317","article-title":"British Thoracic Society guidelines for the management of spontaneous pneumothorax: Do we comply with them and do they work?","volume":"15","author":"T Soulsby","year":"1998","journal-title":"Emerg Med J"},{"issue":"1","key":"pone.0254866.ref007","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000463380","article-title":"Pneumothorax during pazopanib treatment in patients with soft-tissue sarcoma: Two case reports and a review of the literature","volume":"10","author":"Y Nakahara","year":"2017","journal-title":"Case Rep Oncol"},{"key":"pone.0254866.ref008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-4-14","article-title":"Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series","volume":"4","author":"AJ Verschoor","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"pone.0254866.ref009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1155\/2008\/136708","article-title":"Necrotizing pneumonia complicated by early and late pneumatoceles","volume":"15","author":"S Al-Saleh","year":"2008","journal-title":"Can Respir J"},{"key":"pone.0254866.ref010","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.18632\/oncotarget.23599","article-title":"Pneumatocele during sorafenib therapy: first report of an unusual complication","volume":"9","author":"P Sangro","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0254866.ref011","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2214\/ajr.150.6.1275","article-title":"Pulmonary pneumatocele: pathology and pathogenesis","volume":"150","author":"MJ Quigley","year":"1988","journal-title":"AJR Am J Roentgenol"},{"key":"pone.0254866.ref012","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-3476(72)80292-0","article-title":"Subpleural emphysema complicating staphylococcal and other pneumonia","volume":"81","author":"GF Boisset","year":"1972","journal-title":"J Pediatr"},{"issue":"3","key":"pone.0254866.ref013","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2008.16.2545","article-title":"Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer","volume":"27","author":"SJ Crabb","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0254866.ref014","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/JTO.0b013e318168c7e9","article-title":"Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer","volume":"3","author":"EM Marom","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"9","key":"pone.0254866.ref015","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jpedsurg.2015.01.005","article-title":"Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory\/recurrent solid tumors","volume":"50","author":"RB Interiano","year":"2012","journal-title":"J Pediatr Surg"},{"issue":"1","key":"pone.0254866.ref016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5152\/TurkThoracJ.2018.030118","article-title":"A case report of secondary simultaneous bilateral pneumothorax due to pazopanib treatment","volume":"19","author":"B \u00c7elik","year":"2018","journal-title":"Turk Thorac J"},{"issue":"1","key":"pone.0254866.ref017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.116.1.263","article-title":"Pulmonary cysts as the sole metastatic manifestation of soft tissue sarcoma: case report and consideration of the pathogenesis","volume":"116","author":"S Hasegawa","year":"1999","journal-title":"Chest"},{"issue":"8","key":"pone.0254866.ref018","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"RJ Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0254866.ref019","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/00498254.2012.734642","article-title":"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer","volume":"43","author":"Y Deng","year":"2013","journal-title":"Xenobiotica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T17:40:26Z","timestamp":1626457226000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254866"}},"subtitle":[],"editor":[{"given":"Robert S.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0254866","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]}}}